Clinical Trial Update: Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and biological activity of AMX0035 for Alzheimer's disease has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AMX0035 (sodium phenylbutyrate and tauroursodeoxycholic acid)

Snippet

Sponsor: Amylyx Pharmaceuticals Inc. | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-03-07